✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
PF-06651600 is an investigational drug.
There have been 30 clinical trials for PF-06651600. The most recent clinical trial was a Phase 3 trial, which was initiated on December 3rd 2018.
The most common disease conditions in clinical trials are Alopecia Areata, Alopecia, and Arthritis, Rheumatoid. The leading clinical trial sponsors are Pfizer and [disabled in preview].
There is one US patent protecting this investigational drug and fifty-one international patents.
Recent Clinical Trials for PF-06651600
|Study to Evaluate the Effect of Multiple-Dose Ritlecitinib on the Pharmacokinetics (PK) of Tolbutamide||Pfizer||Phase 1|
|A Target Occupancy Study With Ritlecitinib.||Pfizer||Phase 1|
|Estimation of the Effect of Multiple Dose Ritlecitinib (PF-06651600) on the Pharmacokinetics of a Single Dose of Caffeine in Healthy Participants||Pfizer||Phase 1|
Top disease conditions for PF-06651600
Top clinical trial sponsors for PF-06651600
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|PF-06651600||See Plans and Pricing||Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides||Pfizer Inc. (New York, NY)||See Plans and Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|PF-06651600||Argentina||AR099363||2033-12-05||See Plans and Pricing|
|PF-06651600||Australia||AU2014358792||2033-12-05||See Plans and Pricing|
|PF-06651600||Brazil||BR112016012262||2033-12-05||See Plans and Pricing|
|PF-06651600||Canada||CA2932425||2033-12-05||See Plans and Pricing|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|